| Drug NDC: | 17089-291 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Guna-lympho |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Apis Mellifera - Calendula Officinalis Flower - Centella Asiatica - Dodecahydroxycyclohexane Dihydrate - Equisetum Hyemale - Fumaric Acid - Goldenseal - Graphite - Juglans Regia Leaf - Levothyroxine - Magnesium Phosphate - Malic Acid - Myosotis Arvensis - Phytolacca Americana Root - Sarsaparilla - Sodium Diethyl Oxalacetate - Sodium Pyruvate - Sus Scrofa Capillary Tissue - Sus Scrofa Small Intestine Mucosa Lymph Follicle - Sus Scrofa Vein - Taraxacum Officinale - |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Guna Spa |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Solution/ Drops |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | APIS MELLIFERA - 8 [hp_X]/30mL CALENDULA OFFICINALIS FLOWER - 1 [hp_X]/30mL CENTELLA ASIATICA - 1 [hp_X]/30mL DODECAHYDROXYCYCLOHEXANE DIHYDRATE - 6 [hp_X]/30mL EQUISETUM HYEMALE - 3 [hp_X]/30mL FUMARIC ACID - 6 [hp_X]/30mL GOLDENSEAL - 1 [hp_X]/30mL GRAPHITE - 30 [hp_X]/30mL JUGLANS REGIA LEAF - 3 [hp_X]/30mL LEVOTHYROXINE - 12 [hp_X]/30mL Load more... MAGNESIUM PHOSPHATE, TRIBASIC, PENTAHYDRATE - 6 [hp_X]/30mL MALIC ACID - 6 [hp_X]/30mL MYOSOTIS ARVENSIS - 3 [hp_X]/30mL PHYTOLACCA AMERICANA ROOT - 3 [hp_X]/30mL SARSAPARILLA - 3 [hp_X]/30mL SODIUM DIETHYL OXALACETATE - 6 [hp_X]/30mL SODIUM PYRUVATE - 6 [hp_X]/30mL SUS SCROFA CAPILLARY TISSUE - 6 [hp_X]/30mL SUS SCROFA SMALL INTESTINE MUCOSA LYMPH FOLLICLE - 6 [hp_X]/30mL SUS SCROFA VEIN - 6 [hp_X]/30mL TARAXACUM OFFICINALE - 1 [hp_X]/30mL |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 23 May, 2006 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 19 Jun, 2026 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | Guna spa |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| NUI: | N0000185021 N0000175629 N0000184306 N0000185001 M0000728 M0002274 N0000175945 M0021504 |
| Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT). | |
| UNII: | 7S82P3R43Z P0M7O4Y7YD 7M867G6T1U 5BWD2J7B4W 59677RXH25 88XHZ13131 ZW3Z11D0JV 4QQN74LH4O 85HKB87105 Q51BO43MG4 Load more... 453COF7817 817L1N4CKP C73BK97H5J 11E6VI8VEG 2H1576D5WG 6CA025Y4FG POD38AIF08 253A0356PN 308LM01C72 2510RH3I89 39981FM375 |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class EPC: | Standardized Insect Venom Allergenic Extract [EPC] l-Thyroxine [EPC] |
| Established pharmacologic class associated with an approved indication of an active moiety (generic drug) that the FDA has determined to be scientifically valid and clinically meaningful. Takes the form of the pharmacologic class, followed by `[EPC]` (such as `Thiazide Diuretic [EPC]` or `Tumor Necrosis Factor Blocker [EPC]`. | |
| Pharmacologic Class PE: | Increased Histamine Release [PE] Cell-mediated Immunity [PE] Increased IgG Production [PE] |
| Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`. | |
| Pharmacologic Class CS: | Allergens [CS] Bee Venoms [CS] Thyroxine [CS] |
| Chemical structure classification of the drug product’s pharmacologic class. Takes the form of the classification, followed by `[Chemical/Ingredient]` (such as `Thiazides [Chemical/Ingredient]` or `Antibodies, Monoclonal [Chemical/Ingredient]. | |
| Pharmacologic Class: | Allergens [CS] Bee Venoms [CS] Calculi Dissolution Agent [EPC] Cell-mediated Immunity [PE] Increased Histamine Release [PE] Increased IgG Production [PE] Increased Large Intestinal Motility [PE] Inhibition Large Intestine Fluid/Electrolyte Absorption [PE] Inhibition Small Intestine Fluid/Electrolyte Absorption [PE] Magnesium Ion Exchange Activity [MoA] Osmotic Activity [MoA] Osmotic Laxative [EPC] Standardized Insect Venom Allergenic Extract [EPC] Stimulation Large Intestine Fluid/Electrolyte Secretion [PE] Thyroxine [CS] l-Thyroxine [EPC] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 17089-291-18 | 1 BOTTLE, DROPPER in 1 BOX (17089-291-18) / 30 mL in 1 BOTTLE, DROPPER | 21 Dec, 2018 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.